Program

Program Monday, 31 October 2016

7:30 - 8:30
EDUCATIONAL SYMPOSIUM
7:30 - 8:30
Room: Hall D (L -2)
THE BIOSIMILAR EFFECT: HOW REAL-WORLD EVIDENCE WILL INFLUENCE ADOPTION OF BIOSIMILAR SPECIALTY THERAPIES

(Sponsored by Cardinal Health)

8:45 - 10:45
WELCOME & FIRST PLENARY SESSION
Room: Hall A (L2)
WELCOME FROM ISPOR CEO/EXECUTIVE DIRECTOR
Nancy S. Berg
CEO & Executive Director, ISPOR, Lawrenceville, NJ, USA
Room: Hall A (L2)
PRESIDENTIAL ADDRESS
Lou Garrison, PhD bio
2016-2017 ISPOR President and Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
Room: Hall A (L2)
CONGRESS PROGRAM OVERVIEW
Hans-Georg Eichler, MD, MSc bio
Senior Medical Officer, European Medicines Agency (EMA), London, UK
Tomasz Hermanowski, PhD
InterQuality Project Leader and Professor & Head, Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
Room: Hall A (L2)
FIRST PLENARY SESSION: WHAT SYNERGIES COULD BE CREATED BETWEEN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENTS?
Decisions taken by regulators and health care payers, the latter informed by HTA bodies, determine which patient groups have access to new therapies and at what point in time. While these decision makers have different roles, they often rely on almost the same scientific data about new products; they also share the broad goal of enabling access for patients to beneficial therapies. Yet, formal interactions and collaboration between regulators and the HTA bodies that inform payers have only started in recent years in the European Union (EU) and are mostly in a pilot stage. This plenary session explores hitherto unrealised synergies in the work and processes of regulators and HTA bodies. Panelists will also address the roadblocks in the EU health sector ecosystem that need to be removed in order to realise the synergies while respecting their different roles. 
Moderator: Hans-Georg Eichler, MD, MSc bio
Senior Medical Officer, European Medicines Agency (EMA), London, UK
Speaker: Guido Rasi
Executive Director, European Medicines Agency (EMA), London, UK
Speaker: Wim Goettsch, PhD
Secretariat Director, EUnetHTA JA3, Diemen, The Netherlands
Speaker: Andrzej Rys
Director, Health Systems, Medical Products and Innovation, European Commission, Brussels, Belgium
Speaker: Jens Grueger, PhD
Vice President & Head of Global Pricing & Market Access, F. Hoffmann-LaRoche, Basel, Switzerland
8:45 - 14:15
RESEARCH POSTER PRESENTATIONS - SESSION I
10:45 - 11:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
11:15 - 12:15
BREAKOUT SESSION

11:15 - 12:15
Room: Hall A (L2)

IP1: PATIENT-CENTERED DECISION-MAKING WITH MULTI-CRITERIA DECISION ANALYSIS: SHOULD WE BE TRYING TO QUANTIFY THE PATIENT VOICE FOR USE IN HEALTH TECHNOLOGY ASSESSMENT?

Moderator:

J Jaime Caro, MDCM, FRCPC, FACP, Chief Scientist, Evidera, Lexington, MA, USA and Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada

Panelists:

Lars Sandman, PhD, Professor, National Centre for Priority Setting in Health-Care, Linköping University, Linköping, Sweden

Peter L. Kolominsky, MD, PhD, MBA, Professor & Director, Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health, University of Erlangen - Nürnberg, Germany, Erlangen, Germany

Alaa Hamed, MD, MPH, MBA, Head, Rare Disease, Patient Outcomes and Medical Economics, Genzyme, a Sanofi Company, Cambridge, MA, USA


11:15 - 12:15
Room: Hall D (L -2)

IP2: NATIONAL HTA PROCESS AND EUROPEAN COOPERATION ON HTA--FIT FOR PURPOSE? (Invited Issue Panel)

Moderator:

Finn Børlum Kristensen, MD, PhD, Professor, University of Southern Denmark, Hilleroed, Denmark bio

Panelists:

Dominik Schnichels, Head of Unit, DG SANTE B4, Medical Products: Quality, Safety, Innovation, European Commission, Brussels, Belgium bio

Zoe Garrett, MRes, MPhil, Senior Technical Adviser, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester, UK bio

Rui Santos Ivo, Vice-President, Executive Board, National Authority of Medicines and Health Products (INFARMED), Lisbon, Portugal bio

Tomas Tesar, PharmD, PhD, MBA, MSc, Member, Reimbursement Committee, Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovak Republic bio


11:15 - 12:15
Room: Hall E1 (L0)
W1: THE NEW NICE CANCER DRUGS FUND TECHNOLOGY APPRAISAL PROCESS: YOUR QUESTIONS ANSWERED
Discussion Leaders:

Meindert Boysen, PharmD, MSc, Professor, Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, UK

David Tyas, PhD, Associate Director, Health Economics and Outcomes Research, Bristol-Myers Squibb, Uxbridge, UK

Caroline Ling, PhD, Senior Director, Market Access and Outcomes Strategy, RTI Health Solutions, Manchester, UK

Sorrel Wolowacz, PhD, Head, European Health Economics, RTI Health Solutions, Manchester, UK


11:15 - 12:15
Room: Hall E2 (L0)
W2: MOVING THE SCIENCE FORWARD: PSYCHOMETRIC CONSIDERATIONS AND STUDY DESIGNS FOR UNDERSTANDING MEANINGFUL CHANGE AND CONDUCTING MIXED METHODS RESEARCH
Discussion Leaders:

Stacie Hudgens, MA, Managing Partner, Strategic Lead, Clinical Outcomes Solutions, Tucson, AZ, USA

Tara Symonds, PhD, COA Strategy Lead & Partner, Clinical Outcomes Solutions Ltd., Folkestone, Kent, UK

Lori McLeod, PhD, Director of Psychometrics, RTI Health Solutions, Research Triangle Park, NC, USA

Cheryl Coon, PhD, Principal, Outcometrix, Tucson, AZ, USA


11:15 - 12:15
Room: Hall F1 (L0)
W3: UTILITIES IN ECONOMIC EVALUATION: USING BEST PRACTICES WHERE INTERNATIONAL GUIDELINES PROVIDE INSUFFICIENT DETAIL
Discussion Leaders:

John Brazier, PhD, MSc, Professor of Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

Roberta Ara, MSc, Senior Research Fellow, School of Health and Related Research, The University of Sheffield, Sheffield, UK

Helene Chevrou-Severac, PhD, Global Head of Health Economics and HTA, Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland


11:15 - 12:15
Room: Hall F2 (L0)
P1: MODELING METHODS
Moderator: Matthew Taylor, MSc, PhD
Director, York Health Economics Consortium, York, UK

MO1

11:15 - 11:30

WITHDRAWN

MO2

11:15 - 11:30

CONSIDERING OR NOT ADVERSE EVENTS IN HEALTH ECONOMIC MODELS: A PRAGMATIC APPROACH

Roze S, Cartier-Bechu C, Gherardi A, Monnier R, Pignata M, Petijean A, Sivignon M
HEVA HEOR Sarl, Lyon, France

MO3

11:30 - 11:45

THE IMPACT OF DYNAMIC TRANSMISSION MODELLING ON THE ESTIMATED COST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HEPATITIS C IN THE UNITED KINGDOM

Madin-Warburton M1, Pitcher A1, Martin N2
1IMS Health, London, UK, 2University of California San Diego, San Diego, CA, USA

MO4

11:45 - 12:00

THE IMPACT OF EXTRAPOLATING SURVIVAL BASED ON CURE MODELS: COMPARING MEAN INCREMENTAL SURVIVAL AND CURE RATES IN DIFFERENT DATASETS

van Oostrum I1, Postma MJ2, Buskens E3, Heeg BM1
1Ingress-health Netherlands, Rotterdam, The Netherlands, 2University of Groningen, Groningen, The Netherlands, 3University Medical Center Groningen, Groningen, The Netherlands
12:15 - 14:15
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I
12:30 - 13:45
OPEN MEETING: STATISTICAL METHODS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH SPECIAL INTEREST GROUP
Room: Hall E1 (L0)
All ISPOR members with an interest in statistical methodology are welcome to attend this newly formed Special Interest Group focusing on strengthening the use of appropriate statistical methodology and evaluating and improving the analytic techniques used in real world data analysis.
12:45 - 13:45
ISPOR STUDENT RESEARCH SHOWCASE
Room: Hall F2 (L0)
HAVING A HIGH IMPACT ON MANAGING ACCESS TO MEDICAL INNOVATION: STRENGTHENING THE METHODOLOGY-POLICY NEXUS

This showcase session will feature four outcomes research studies, conducted by ISPOR student members and presented during the ISPOR 19th Annual European Congress. A brief summary of the research study and conclusions will be presented by each student author followed by a discussion on Having a High Impact on Managing Access to Medical Innovation: Strengthening The Methodology-Policy Nexus

Moderator: Dennis Raisch, PhD
Professor, College of Pharmacy, University of New Mexico, Albuquerque, NM, USA
Moderator: Laura Pizzi, PhD
Professor, College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA
Moderator: Zeba M. Khan, MS, RPh, PhD
Vice President, Celgene Corporation, Summit, NJ, USA
Speaker: Amr Makady, MSc
Policy Advisor, The National Healthcare Institute (ZIN), Diemen , The Netherlands
Speaker: Bettina Wulff Risør, MPH
PhD Student, University of Southern Denmark, Odense, Denmark
Speaker: Frank Moriarty
HRB PhD Scholar, Royal College of Surgeons in Ireland, Dublin, Ireland
Speaker: Gerrit L. Merkens, BSc
Student, Utrecht University, Utrecht , The Netherlands
12:45 - 13:45
EDUCATIONAL SYMPOSIUM
12:45 - 13:45
Room: Hall D (L -2)
INCREASING EUROQOL (EQ-5D) FROM 3 TO 5 LEVELS: IMPLICATIONS FOR USERS - DOES "NEW" MEAN "BETTER"?

(Sponsored by EuroQol Research Foundation)

13:15 - 14:15
POSTER AUTHOR DISCUSSION HOUR - SESSION I
14:15 - 15:15
BREAKOUT SESSION

14:15 - 15:15
Room: Hall E2 (L0)

IP3: DOES CONSERVATISM BY REGISTRATION AUTHORITIES IN THEIR REQUIREMENTS FOR OUTCOME MEASURES IN PAIN TRIALS HAMPER DRUG DEVELOPMENT IN THAT AREA?

Moderator:

R.L Akehurst, PhD, Strategic Director, Sheffield, BresMed Health Solutions, Sheffield, UK

Panelists:

Will Dunlop, MEc, Head of Market Access, Mundipharma International Ltd, Cambridge, UK

C. Daniel Mullins, PhD, Professor & Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA

Ben van Hout, Professor of Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK


14:15 - 15:15
Room: Hall D (L -2)

IP4: DOES EUROPEAN REAL WORLD DATA REQUIRE A ‘DIGITAL SCHENGEN’ TO SUPPORT FEDERATED ACCESS, ASSESSMENT, AND (RE)USE, OPENING BORDERS AT THE INSTITUTE TO CROSS-COUNTRY?

Moderator:

Ömer Saka, MD, MSc, Partner, Market Access Strategy and HEOR, Deloitte, Diegem, Belgium

Panelists:

Sarah Garner, PhD, BPharm, Associate Director of Science Policy and Research, National Institute for Health and Care Excellence (NICE), London, UK

Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency, London, UK

Johan van der Lei, MD, PhD, Chair of the Department of Medical Informatics, Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands


14:15 - 15:15
Room: Hall E1 (L0)
W4: UNDERSTANDING THE CHALLENGES FACING THE VALUE ASSESSMENT OF MEDICAL DEVICES
Discussion Leaders:

Richard Charter, MSc, Head of Market Access & Pricing Diabetes Care Europe, Becton Dickinson AG, Allschwil, Switzerland

Carla Zema, PhD, Director, Health Policy and Economics, ZOLL, Pittsburgh, PA, USA

Chantale Lessard, RPh, MSc, PhD, DcomplD, Adjunct Professor, Department of Health Management, Evaluation and Policy, School of Public Health, University of Montreal, Montreal, QC, Canada


14:15 - 15:15
Room: Hall A (L2)
W5: NEW APPROACHES TO SURVIVAL MODELING IN ONCOLOGY
Discussion Leaders:

Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK

Jack Ishak, PhD, Senior Research Leader, Modeling & Simulation, Evidera, Montreal, QC, Canada

Federico Felizzi, PhD, HTA Statistician, GPMA, F. Hoffmann La Roche, Basel, Switzerland

Aline Gauthier, MSc, Managing Director, Health Economics and Market Access, Amaris, London, UK

Victoria Federico Paly, MHS, Senior Health Economist, ICON Health Economics & Epidemiology, New York, NY, USA


14:15 - 15:15
Room: Hall F1 (L0)
P2: STUDIES ON HTA APPROACHES
Moderator: Gerry Oster, PhD bio
Managing Partner, Policy Analysis Inc. (PAI), Brookline, MA, USA

HT1

14:15 - 14:30

ALIGNED AND FLEXIBLE? A COMPARATIVE REVIEW OF SMC AND NICE DECISION-MAKING

Johnson H1, Spoors J2, Johnson J1
1Helen Johnson Consulting Ltd, Welwyn Garden City, UK, 2RJW & Partners, Royston, UK

HT2

14:30 - 14:45

A REVIEW OF THE USE OF NETWORK META-ANALYSIS IN NICE SINGLE TECHNOLOGY APPRAISALS

Fleetwood K1, Glanville J2, McCool R2, Wood H2, Wilson K2, Marshall C2, Yellowlees A1, James D1, Toupin S1, McCabe R1
1Quantics Consulting Ltd, Edinburgh, UK, 2York Health Economics Consortium Ltd, York, UK

HT3

14:45 - 15:00

ACTUARIAL APPROACHES TO MODELLING AND MITIGATING FINANCIAL UNCERTAINTY IN RECOMMENDING NEW HEALTH TECHNOLOGIES

Serre D, Buckle J
Milliman, London, UK

HT4

15:00 - 15:15

IMPLEMENTATION OF CONDITIONAL REIMBURSEMENT SCHEMES IN HTA PRACTICE: EXPERIENCES FROM THE NETHERLANDS

Makady A1, Nijmeijer H2, de Boer A3, Hillege JL4, Klungel O5, Goettsch W1
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2Radboud University Medical Centre, Nijmegen, The Netherlands, 3Utrecht University, Utrecht, The Netherlands, 4University Medical Center Groningen, Groningen, The Netherlands, 5Utrecht University, UTRECHT, The Netherlands

14:15 - 15:15
Room: Hall F2 (L0)
P3: UTILITY STUDIES
Moderator: Ursula Rochau, Ass.-Prof., MD, MSc
Assistant Professor, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research and HTA/ ONCOTYROL - Center for Personalized Medicine, Hall i.T./ Innsbruck, Austria

UT1

14:15 - 14:30

UTILITY BY TREATMENT LINE IN MULTIPLE MYELOMA; ANALYSIS OF OVER 9000 EQ-5Q-3L QUESTIONNAIRES FROM THE EMMOS REGISTRY

Hatswell AJ1, Couturier C2, Ito T3
1BresMed, Sheffield, UK, 2Janssen Medical Affairs, Paris, France, 3Janssen Health Economics & Market Access EMEA, High Wycombe, UK

UT2

14:30 - 14:45

A META REGRESSION ANALYSIS OF UTILITY WEIGHTS FOR BREAST CANCER

Gong JR, Lim J, Bae S
Ewha Womans University, Seoul, South Korea

UT3

14:45 - 15:00

PROSPECTIVE UTILITY STUDY OF PATIENTS WITH MULTIPLE CARDIOVASCULAR EVENTS

Pockett RD1, McEwan P2, Ray J3, Tran I4, Shutler S5, Martin S6, Yousef Z7, Bakhai A8
1Swansea University, Swansea, UK, 2Health Economics and Outcomes Research Ltd, Cardiff, UK, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Roche Products Ltd, Welwyn Garden City, UK, 5F. Hoffmann-La Roche Ltd., Basel, Switzerland, 6Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, UK, 7University Hospital of Wales, Cardiff, UK, 8Royal Free London NHS Foundation Trust, Barnet, UK

UT4

15:00 - 15:15

MAPPING QUALITY OF LIFE SCORES FROM FACT-G, FAACT AND FACIT-F ONTO PREFERENCE-BASED UTILITIES USING THE 5-LEVEL VERSION OF EQ-5D QUESTIONNAIRE

Meregaglia M1, Borsoi L1, Cairns J2, Tarricone R1
1Bocconi University, Milan, Italy, 2London School of Hygiene and Tropical Medicine, London, UK
15:15 - 15:45
BREAK & EXHIBITS VIEWING
15:45 - 16:45
BREAKOUT SESSION

15:45 - 16:45
Room: Hall A (L2)

IP5: A "FEDERAL" STANDARD FOR VALUING HEALTH IN A POST-REFERENDUM EUROPE?

Moderator:

Meindert Boysen, PharmD, MSc, Professor, Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, and Programme Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), London, UK

Panelists:

Paul Kind, Professor, Centre for Health Economics, Management and Policy, HSE University, St. Petersburg, Russia

Ben van Hout, PhD, Professor of Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK


15:45 - 16:45
Room: Hall E1 (L0)

IP6: FROM TESTIMONIALS TO QUALITATIVE RESEARCH EMBEDDED IN CLINICAL TRIALS: HOW DO HEALTH TECHNOLOGY ASSESSMENT BODIES CONSIDER THE VOICE OF RARE DISEASE PATIENTS WHEN GRANTING ACCESS TO ORPHAN DRUGS?

Moderator:

Benoit Arnould, PhD, Senior Director, Patient-Centered Outcomes, Mapi Group, Lyon, France

Panelists:

Sheela Upadhyaya, MSc, Associate Director, Centre for Health Technology Evaluation, Highly Specialised Technologies, National Institute for Health and Care Excellence, London, UK

Christine Lavery, MBE, Group Chief Executive, The Society for Mucopolysaccharide Diseases, London, UK

Samantha Parker, MBA, Senior Vice President, Patient Access Officer, Lysogene, Neuilly sur Seine, France


15:45 - 16:45
Room: Hall D (L -2)
W6: BRIDGING THE GAP BETWEEN EFFICACY AND EFFECTIVENESS: METHODS TO IDENTIFY DRIVERS OF EFFECTIVENESS BEFORE LAUNCH
Discussion Leaders:

Chris Chinn, MSc, ACA, Head of Real World Investigations, Sanofi, Guildford, UK

Clementine Nordon, MD, PhD, Senior Epidemiologist, LASER Analytica, Paris, France

Lifang Liu, MD, PhD, Epidemiologist, EORTC, Brussels, Belgium

Mikkel Z. Ankarfeldt, PhD, Post Doc, Novo Nordisk A/S, Soeborg, Denmark


15:45 - 16:45
Room: Hall E2 (L0)
W7: APPROPRIATE MODEL TIME HORIZONS: THEORY, EMPIRICAL RESULTS, AND THE PERSPECTIVE OF DECISION MAKERS
Discussion Leaders:

Anthony J Hatswell, MSc, Principal Consulting Economist, Department of Statistical Science, University College London, London, UK

Uwe Siebert, MD, MPH, MSc, ScD, Professor & Chair, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Austria, Adjunct Professor, Health Policy and Management, Harvard School of Public Health, Boston, MA, USA, and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

Ash Bullement, BSc, Health Economist, BresMed Health Solutions, Sheffield, UK

Matthew Taylor, MSc, PhD, Director, York Health Economics Consortium, Heslington, York, UK


15:45 - 16:45
Room: Hall F1 (L0)
P4: CARDIOVASCULAR OUTCOMES RESEARCH STUDIES
Moderator: Daniel Gladwell
Principal Consultant, BresMed, Sheffield, UK

CV4

16:30 - 16:45

ARE COMPONENT ENDPOINTS EQUAL? A STUDY INTO THE PRACTICE OF COMPOSITE END POINTS IN CLINICAL TRIALS

Vaanholt MC1, von Birgelen C2, Kok M3, Weernink MG1, van Til J2
1University Twente, Enschede, The Netherlands, 2University of Twente, Enschede, The Netherlands, 3Medisch Spectrum Twente, Enschede, The Netherlands

CV1

15:45 - 16:00

COMPARISON OF ORAL ANTI-COAGULANTS FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION: TWO MULTI-CRITERIA DECISION ANALYSES

Tervonen T1, Ustyugova AV2, Lip G3, Verdecchia P4, Sri Bhashyam S1, Heinrich-Nols J5, Gropper S5, Kwan R6, Marsh K1
1Evidera Ltd, London, UK, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 3University of Birmingham, Birmingham, UK, 4Hospital of Assisi, Assisi, Italy, 5Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, 6Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada

CV2

16:00 - 16:15

USING SUBPOPULATION TREATMENT EFFECT PATTERN PLOT TO IDENTIFY MORE EFFICIENT RESOURCE ALLOCATION POLICIES

Cao Q1, Hillege JL2, Postma MJ2, Buskens E2, Postmus D3
1University of Groningen, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands, 3University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

CV3

16:15 - 16:30

POLICY OBJECTIVE OF GENERIC MEDICINES FROM THE INVESTMENT PERSPECTIVE: THE CASE OF CLOPIDOGREL

Elek P1, Harsányi A2, Zelei T3, Csetneki K3, Kaló Z3
1Eötvös Loránd University (ELTE), Budapest, Hungary, 2Eötvös Loránd University, Budapest, Hungary, 3Syreon Research Institute, Budapest, Hungary

15:45 - 16:45
Room: Hall F2 (L0)
P5: PRICING POLICY STUDIES
Moderator: Mitja Kos, PhD
Associate Professor, Chair of Social Pharmacy, University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia

PR1

15:45 - 16:00

ASSOCIATION BETWEEN THE PRICES OF ORPHAN DRUGS IN ONCOLOGY AND THE PATIENT POPULATION SIZES

Jarosławski S, Toumi M
Aix-Marseille University, Marseille, France

PR2

16:00 - 16:15

PAY FOR PERFORMANCE: A PROPOSAL FOR AND SIMULATION OF REAL TIME OUTCOMES-BASED PHARMACEUTICAL PRICING USING ROUTINELY COLLECTED DATA

Butt T1, Lee A2, Tufail A3
1University College London, London, UK, 2University of Washington, Seattle, WA, USA, 3Moorfields Eye Hospital NHS Foundation Trust, London, UK

PR3

16:15 - 16:30

DIFFERENCES IN PRICING POLICIES FOR GENERIC AND BIOSIMILAR MEDICINES

Vogler S, Schneider P, Gombocz M, Zimmermann N
Gesundheit Österreich GmbH / Austrian Public Health Institute, Vienna, Austria

PR4

16:30 - 16:45

THE DETERMINANTS OF INNOVATIVE DRUGS PRICES: THE CASE OF ONCOLOGY DRUGS, COMPARATIVE ANALYSIS

Aissaoui A1, Levy P2
1Paris Dauphine University, PSL, Paris, France, 2Université Paris-Dauphine, Paris, France
15:45 - 19:45
RESEARCH POSTER PRESENTATIONS - SESSION II
17:00 - 18:00
BREAKOUT SESSION

17:00 - 18:00
Room: Hall D (L -2)

IP7: HOW SHOULD BIOSIMILARS BE VALUED AND SHOULD THEY UNDERGO HEALTH TECHNOLOGY ASSESSMENT?

Moderator:

Jeanette Kusel, MSci, MSc, Head of HTA and Health Economics, Costello Medical Consulting Ltd, Cambridge, UK

Panelists:

Frank McKenna, MD, FRCP, Consultant Rheumatologist, Trafford General Hospital, Central Manchester University Hospitals, Manchester, UK

Andrew Walker, PhD, Health Economist, Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK

Emi Psachoulia, MSc, PhD, Senior Manager Market Access, Biogen International GmbH, Zug, Switzerland


17:00 - 18:00
Room: Hall E1 (L0)

IP8: IS THE GOAL OF UNIVERSAL COMPARATIVE EFFECTIVENESS EVIDENCE ACROSS JURISDICTIONS ACHIEVABLE?

Moderator:

Pall Jonsson, PhD, Senior Scientific Adviser, Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE), Manchester, UK

Panelists:

Rob Thwaites, MA, Senior Director, Takeda, London, UK

Hans-Georg Eichler, MD, MSc, Senior Medical Officer EMA, European Medicines Agency, London, UK

Sarah Garner, PhD, BPharm, Associate Director of Science Policy and Research, National Institute for Health and Care Excellence (NICE), London, UK


17:00 - 18:00
Room: Hall A (L2)
W8: THE IMPORTANCE OF RELEVANCE IN HEALTH ECONOMIC EVALUATIONS: CHALLENGES AND WAYS FORWARD
Discussion Leaders:

Herbert J.A. Rolden, PhD, Postdoctoral Researcher, Radboud Institute for Health Sciences, Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands

J. Jaime Caro, MDCM, FACP, FRCPC, Adjunct Professor, Medicine, Epidemiology, and Biostatistics, McGill University, Montreal and Chief Scientist, Evidera, Inc., Lexington, MA, USA

Manuela A. Joore, PhD, Professor of Health Technology Assessment & Decision Making, Department of Clinical Epidemiology and Medical Technology Assessment, School for Public Health and Primary Care (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University Medical Center, Maastricht University, Maastricht, The Netherlands

Janneke P.C. Grutters, PhD, Assistant Professor, Radboud Institute for Health Sciences, Department for Health Evidence, Radboudumc, Nijmegen, The Netherlands


17:00 - 18:00
W9: WITHDRAWN
Discussion Leaders:

17:00 - 18:00
Room: Hall F1 (L0)
P6: MEDICATION ADHERENCE STUDIES
Moderator: Lorenzo G. Mantovani
Professor (Associate), Public Health, Department of Statistics and Quantitative Methods, School of Medicine, University of Milano-Bicocca, Monza, Italy

AD1

17:00 - 17:15

REAL-WORLD IMPACT OF GENDER, AGE AND SOCIO-ECONOMIC STATUS ON TYPE-2 DIABETES MELLITUS (T2DM) PATIENTS DISEASE ENGAGEMENT AND ADHERENCE WITH TREATMENT REGIMENS

Higgins V, Leith A, Benford M, Siddall J, Piercy J
Adelphi Real World, Bollington, UK

AD2

17:15 - 17:30

A FRAMEWORK FOR MEASURING ADHERENCE TO MULTIPLE MEDICATIONS

Pednekar P1, Agh T2, Raval A3, Malmenäs M4, Peterson AM5, Bennett B6, Abrahamyan L7, Bunz TJ2, Borah BJ8, Hutchinson D9, Hiligsmann M10, Manias E11, Williams A12, Turcu-Stiolica A13, Zeber J14
1University of the Sciences, Philadelphia, PA, USA, 2Syreon Research Institute, Budapest, Hungary, 3Healthcore, Inc., Wilmington, DE, USA, 4PAREXEL International, Stockholm, Sweden, 5University of the Sciences in Philadelphia, Philadelphia, PA, USA, 6Adelphi Values Ltd, Bollington, UK, 7University of Toronto, Toronto, ON, Canada, 8Mayo Clinic College of Medicine, Rochester, MN, USA, 9Pharmacy Networks, CVS Caremark, Scottsdale, AZ, USA, 10Maastricht University, Maastricht, The Netherlands, 11Deakin University, Burwood, Australia, 12Monash University, Clayton, Australia, 13Faculty of Pharmacy, University of Medicine and Pharmacy, Craiova, Romania, 14Center for Applied Health Research, Temple, TX, USA

AD3

17:30 - 17:45

MEDICATION ADHERENCE AND PERSISTANCE IN TYPE 2 DIABETES MELLITUS (T2DM): PATIENTS PERSPECTIVE IN THE SPANISH HEALTH CARE SYSTEM

Labrador Barba E1, Hernandez Mijares A2, Alonso Moreno FJ3, Rodriguez de Miguel M1, Orera Peña ML1, Aceituno Mata S4, Perez L4, Faus Dader MJ5
1Mylan, Barcelona, Spain, 2Dr. Peset Hospital, Valencia, Spain, 3Sillería Health Center, Toledo, Spain, 4Outcomes’10, Castellon, Spain, 5Faculty of Pharmacy, Granada, Spain

AD4

17:45 - 18:00

ADHERENCE TO TREATMENT AND MODIFIABLE RISK FACTORS IN ACUTE CORONARY SYNDROME (ACS) PATIENTS REGISTERED IN THE PGRX REAL WORLD DATASETS

Cuervo J1, Nordon C2, Rossignol M3, Morisot N2, Benichou J4, Danchin N5, Abenhaim L6, Grimaldi-Bensouda L2
1HEOR, Oviedo, Spain, 2LASER Analytica, Paris, France, 3McGill University, Montreal, QC, Canada, 4Centre Hospitalier Universitaire de Rouen, Paris, France, 5Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France, 6LASER Analytica, London, UK

17:00 - 18:00
Room: Hall F2 (L0)
F1: EXTENDING COST-EFFECTIVENESS ANALYSIS, PARTIAL OPTIMIZATION MODELLING, AND FISCAL MODELLING IN VACCINE VALUE ASSESSMENTS
Moderator:

Hans Severens, PhD, Professor, Evaluation in Health Care, iBMG - Institute of Health Policy & Management and iMTA - Institute of Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

Speakers:

Baudouin Standaert, MD, PhD, Director, Health Economics, GSK Vaccines, Wavre, Belgium

Mark Connolly, PhD, Guest Researcher, University of Groningen, the Netherlands and Managing Director, Global Market Access Solutions LLC, Geneva, Switzerland

Raymond Hutubessy, PhD, MSc, Senior Health Economist, Initiative for Vaccine Research, World Health Organization (WHO), Geneva, Switzerland

18:00 - 19:45
EXHIBITORS' OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
18:15 - 19:15
BREAKOUT SESSION

18:15 - 19:15
Room: Hall D (L -2)
F2: PATIENT ENGAGEMENT: STOPPING TO DEFINE IT
Moderator:

Todd Berner, MD, Head Global Medical Affairs Strategy, Immunology, Baxalta, Bannockburn, IL, USA

Speakers:

Eleanor M. Perfetto, PhD, RPh, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC, USA and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA

Maya L. Hanna, MPH, Doctoral Student, School of Pharmacy, University of Maryland, Baltimore, MD, USA

Rob Camp, BS, Communications Manager, European Patients' Academy (EUPATI), Barcelona, Spain

Russell Wheeler, Patient Advocate, Leber Hereditary Optic Neuropathy, Winchester, UK


18:15 - 19:15
Room: Hall A (L2)
F3: GENERATING EVIDENCE OF THE ADDED VALUE OF ‘PRECISION’ MEDICINE
Moderator:

Katherine Payne, PhD, MSc, DipClinPharm, BPharm, MRPharmS, Professor of Health Economics, The University of Manchester, Manchester, UK

Speakers:

Eric Faulkner, MPH, Vice President, Precision and Transformative Technology Solutions, Value Demonstration, Access and Commercial, Evidera, and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, SC, USA

Uwe Siebert, MD, MPH, MSc, ScD, Professor & Chair, Department of Public Health and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Austria, Adjunct Professor, Health Policy and Management, Harvard School of Public Health, Boston, MA, USA, and Director, Division for HTA, ONCOTYROL – Center for Personalized Cancer Medicine, Hall i.T., Austria

Anke-Peggy Holtorf, PhD, MBA, Managing Director, Health Outcomes Strategies, GmbH, Basel, Switzerland

Gurmit Sandhu, B Pharm (Hons), MBA, MPH, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland


18:15 - 19:15
Room: Hall F2 (L0)
F4: BURDEN OF HEPATITIS C IN CENTRAL AND EASTERN EUROPEAN COUNTRIES
Moderator:

Zoltán Kaló, PhD, Professor of Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary

Speakers:

Guenka Petrova, DSci, Professor, Social Pharmacy, Medical University Sofia, Faculty of Pharmacy, and President, ISPOR Bulgaria Chapter, Sofia, Bulgaria

Lubov Krasnova, MD, PhD, Senior Researcher, Department of Hematology & Geriatrics, First Sechenov State Medical University, Moscow, Russian Federation

Anush Perikhanyan, MPH, Researcher, Pharmaceutical Management, Yerevan State Medical University, and President, ISPOR Armenia Chapter, Yerevan, Armenia

Elena Pyadushkina, PharmD, Researcher, Russian Presidential Academy of National Economy and Public Administration, Moscow, Russian Federation


18:15 - 19:15
Room: Hall F1 (L0)
F5: DRUG PRICING IN ADRIATIC COUNTRIES – IS REFERENCE PRICING THE BEST OPTION?
Moderator:

Tarik Catic, PhD(s), Past President, ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia

Speakers:

Rok Hren, PhD, MSc IHP (HE), Professor, University of Ljubljana, Ljubljana, Slovenia

Ljubica Suturkova, PhD, President, ISPOR Republic of Macedonia Chapter, and Professor, Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia

Pero Draganić, PhD, MD, President, ISPOR Croatia Chapter, and Assistant Professor, HALMED, Zagreb, Croatia

Dragana Atanasijevic, MD, MSc, President, ISPOR Serbia Chapter, and Consultant, HTA & Healthcare Quality Improvement, Belgrade, Serbia


18:15 - 19:15
Room: Hall E1 (L0)
F6: THE ECONOMIC BURDEN OF COUNTERFEIT MEDICINES IN AFRICA: SITUATION ANALYSIS AND PROPOSED SOLUTIONS
Moderator:

Mahmoud Diaa Elmahdawy, PharmD, President, ISPOR Egypt Chapter, Director, AMAC Market Access, Novartis, Health Economics, and Lecturer of Clinical and Hospital Pharmacy, Misr International University, Cairo, Egypt

Speakers:

Kasem Akhras, PharmD, Head, Market Access, Middle East and North Africa (MENA), Novartis Pharma Services AG, Dubai, United Arab Emirates

Ilse Truter, DCom, BPharm, MSc, PhD, MPS, Professor in Pharmacy & Leader, Drug Utilization Research Unit (DURU), Department of Pharmacy, School of Medicinal Sciences, Faculty of Health Sciences, Nelson Mandela Metropolitan University, Port Elizabeth, South Africa


18:15 - 19:15
Room: Hall E2 (L0)
F7: A STRUCTURED DEBATE REGARDING THE NATIONAL HEALTH ECONOMICS GUIDELINES IN SOUTHERN EUROPE
Moderator:

Carlos Gouveia Pinto, PhD, Associate Professor, ISEG, Lisbon School of Economics and Management and President, ISPOR Portugal Chapter, Lisbon, Portugal

Speakers:

Jaime Espín, PhD, Professor, Andalusian School of Public Health, Granada, Spain

Luis Silva Miguel, MSc, PhD, Researcher, Research Centre on the Portuguese Economy, CISEP, Lisbon School of Economics & Management, University of Lisbon, Lisbon, Portugal

Lorenzo G. Mantovani, DSc, Associate Professor of Public Health, Research Centre on Public Health, University of Milano-Bicocca, Monza, Italy

Francesco Saverio Mennini, PhD, Professor, Faculty of Economics, Centre for Economic Evaluation and HTA (EEHTA), CEIS, University of Rome Tor Vergata, Rome, Italy

18:45 - 19:45
POSTER AUTHOR DISCUSSION HOUR - SESSION II
19:45 - 21:00
ISPOR STUDENT WELCOME RECEPTION
Room: Hall K Foyer (L -2)
All students and faculty are welcome to attend! One of the main goals of the ISPOR Student Network is to increase the connection among student members and faculty. Please join us to continue the success and increase your networking connections!
19:45 - 21:00
ISPOR CENTRAL & EASTERN EUROPE (CEE) NETWORK WELCOME RECEPTION
Room: Hall G Foyer (L -2)
Join ISPOR colleagues for a great opportunity to interact, share ideas, and network! ISPOR CEE Network connects over 3700 HEOR professionals from 23 ISPOR Regional Chapters sharing ISPOR values and supporting its vision and mission. All attendees interested in learning about the CEE Network, its role in the HEOR community, current activities and initiatives, are welcome to attend this event. For more information visit www.ispor.org >> Regional Chapters/Networks >> ISPOR Networks Index >> CEE Network. 
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.